Argus Research analyst Taylor Conrad initiates coverage on Haleon (NYSE:HLN) with a Hold rating.
EXCLUSIVE: Adial Pharma’s AD04 Effective In Heavy Drinker Alcohol Use Disorder Patients
Adial Pharmaceuticals Inc's (NASDAQ: ADIL) ONWARD Phase 3 study of AD04 for Alcohol Use Disorder (AUD) achieved a statistically significant mean reduction in heavy drinking days compared to placebo.
